California is currently home to 5591 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma As a Prognostic and Response Diagnostic: LEOPARD
Recruiting
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
Gender:
ALL
Ages:
Between 12 months and 50 years
Trial Updated:
01/17/2025
Locations: Childrens Hospital Los Angeles, Los Angeles, California
Conditions: Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
Parathyroid Tumor Clonal Status
Recruiting
To define the frequency of monoclonal-X and polyclonal-X tumors in PHPT participants having parathyroidectomy (PTX) and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
01/17/2025
Locations: University of California-Department of Surgery, San Francisco, California
Conditions: Parathyroid Tumor, Primary Hyperparathyroidism
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Recruiting
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Gender:
ALL
Ages:
Between 1 day and 6 months
Trial Updated:
01/17/2025
Locations: University of California at Los Angeles, Los Angeles, California
Conditions: Tuberous Sclerosis Complex, Epilepsy
Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors
Recruiting
The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/17/2025
Locations: Participating Site, # 1019, Los Angeles, California
Conditions: Advanced Solid Tumor
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Recruiting
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
01/17/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Crohn's Disease (CD)
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruiting
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), fol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: The Oncology Institute (TOI) Clinical Research, Cerritos, California
Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Reducing Overuse of Antibiotics with Decision Support
Recruiting
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate a... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
01/16/2025
Locations: Benioff Children's Hospital - Oakland, Oakland, California
Conditions: Lower Respiratory Tract Infection, Pneumonia, Asthma, Bronchiolitis, Viral
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Recruiting
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the localized pharmacodynamics (PD) of rilvegostomig, volrustomig, sabestomig, and AZD9592 within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients presenting with Head and Neck Squamous Cell Carcinoma (HNSCC) with a surface accessible lesion, who are scheduled for tumor and/or regional node dissection as part of their standard treatment. PD effects du... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: UC Davis, Sacramento, California
Conditions: Head and Neck Squamous Cell Carcinoma
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
Recruiting
Children with cerebral palsy (CP), Gross Motor Functional Classification Scale (GMFCS) I-II will be recruited to participate in a home based physical activity intervention for 4 weeks. Demographic data will be collected, and validated surveys assessing baseline physical activity level and mobility will be completed. Participants will have an exercise program assigned and will be given a logbook to record their exercise adherence. They will be assigned to the Augment Reality (AR) app group. The A... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
01/16/2025
Locations: Jackie and Gene Autry Orthopedic Center, CHLA, Los Angeles, California
Conditions: Cerebral Palsy, Mobile Phone Use, Pediatric ALL, Physical Disability, Physical Inactivity
IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
01/16/2025
Locations: Feinerman Vision Center, Newport Beach, California
Conditions: Cataract, Presbyopia, Posterior Capsule Opacification
Single-tracer Multiparametric PET Imaging
Recruiting
The overarching goal of this project is to develop and evaluate a single-tracer multiparametric positron emission tomography (PET) imaging solution for simultaneous imaging of blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG) alone. The investigators working hypothesis is that quantitative blood flow can be extracted from dynamic 18F-FDG PET data by use of tracer kinetic modeling, in addition to glucose metabolism that 18F-FDG is conventionally used for.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: UC Davis EXPLORER Molecular Imaging Center, Sacramento, California
Conditions: Healthy Subjects, Cardiovascular Disease